This article was written at the end of last year prior to the recent IPO. One thing of interest is the 20 year sale agreement with Zimmer Biomet (market cap $24.55 Billion) and the worldwide distribution agreement with 3M ($126.05 Billion). I also note that there is a forecast of $20 million sales for 2019 which was not on the current prospectus for various reasons. But if the trajectory is true this would potentially represent revenue growth of over 600% vs 2018 revenue. DYOR and GLTAH!
How the rich invest: Lang Walker backs Next Science's bacteria buster
-
- There are more pages in this discussion • 9 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add NXS (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
27.5¢ |
Change
-0.015(5.17%) |
Mkt cap ! $80.21M | |||
| Open | High | Low | Value | Volume |
| 28.5¢ | 28.5¢ | 26.0¢ | $30.57K | 112.2K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 19549 | 25.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 27.5¢ | 9999 | 1 |
View Market Depth
| Last trade - 16.10pm 26/07/2024 (20 minute delay) ? |
| NXS (ASX) Chart |